Table 4.
Risk factors identified as principal variables for the prediction of clinical CINV endpoints
| Clinical CINV endpoints | Risk factors identified as principal variables | |||
|---|---|---|---|---|
| Overall patient population (n = 710) | Patients on HEC regimens (n = 139) | Patients on AC-based regimens (n = 361) | Patients on XELOX regimens (n = 210) | |
| Overall complete response (CR) | • Fatigue interference (PC4) | • Ex-/current drinkers (PC1) | -- | • Social/chronic drinkers (PC1) |
| • History of chemotherapy-induced vomiting (PC1) | • History of chemotherapy-induced nausea (PC2) | |||
| • Gender (PC4) | • Fatigue interference (PC3) | |||
| Overall complete protection (CP) | -- | • Ex-/current drinkers (PC1) | • Fatigue severity (PC4) | • Fatigue interference (PC3) |
| Overall complete control (CC) | -- | • Ex-/current drinkers (PC1) | • Fatigue severity (PC4) | -- |
| • Fatigue interference (PC3) | ||||
| • Fatigue severity (PC4) | ||||
CR: No vomiting and no rescue antiemetics
CP: No vomiting, no significant nausea and no rescue antiemetics
CC: No vomiting, no nausea and no rescue antiemetics